Study of LTC004 in Subjects With Advanced Malignant Tumors

NCT05666635 | Unknown Phase 1 DMC

• 1 other identifier: LTC004-101
• Study Type: interventional
• Target: 368
• Locations: 0 countries
• Sites: N/A

Brief Summary

This was a multicenter, open, multi-cohort PHASE I study, consisting of 2 phases: Phase Ia (Phase Ia dose escalation) and Phase Ib (Phase Ib multi-cohort expansion). The objective of this study was to evaluate safety, tolerability, pharmacokinetic， Pharmacodynamics and biological characteristics, and initial efficacy in advanced malignant tumors.

Conditions

Adult Solid Tumor

Outcome Measures

Primary Outcomes (2)

• Number of Participants with Adverse Event (AE)

  safety and tolerability as measured by the incidence of treatment-emergent adverse events.

  up to 12 months

• Number of participants with DLTs

  DLTs as measured by the incidence during Cycle 1.

  up to 21 days

Secondary Outcomes (4)

• Objective response rate (ORR)

  up to 12 months

• Serum concentrations of LTC004

  up to 12 months

• Immunogenicity of LTC004

  up to 12 months

• Serum concentrations of cytokines and T cell

  up to 12 months

Study Arms (1)

Experimental：LTC004

EXPERIMENTAL

Monotherapy, dose escalation

Biological: LTC004

Interventions

LTC004 BIOLOGICAL

LTC004 Phase I:Participants will be allocated to one of the following dose groups: 3, 15, 45, 90, 180，270,360 and 450 ug/kg, and receive a treatment of LTC004 followed by 21 days of dose limited toxicity (DLT) observation period. Phase Ib indication exploration Other Name: LTC004 for Injection

Experimental：LTC004

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female aged 18 to 75 years (including upper and lower limit) at the time of signing the informed consent form (ICF)；
• Subjects with locally advanced or metastatic solid tumors or lymphoma who have histologically or cytologically confirmed inoperable disease at screening and have failed from standard treatment，or cannot tolerate standard treatment and/or currently have no effective standard treatment；
• Patients must have at least 1 lesion that qualifies as a target lesion；
• ECOG≤1；
• Life expectancy ≥3 months；
• Adequate organ function；
• Patients who have received any chemotherapy or anti-tumor monoclonal antibody drugs within 4 weeks prior to the first dose of study drug (excluding mitomycin and nitrosoureas within 6 weeks prior to the first dose of study drug）; small molecule targeted drugs within 2 weeks prior to the first dose of study drug; Chinese medicine therapy (Chinese medicine therapy with clear anti-tumor indications in the package insert ）within 4 weeks prior to the first dose of study drug；
• Patients, both females and males, of reproductive potential must agree to use adequate contraception during and for 6 months after the last infusion of LTC004.
• Understands and provides written informed consent and willing to follow the requirements specified in protocol

You may not qualify if:

• History of severe hypersensitivity reactions to other mAbs.
• Untreated, unstable or uncontrolled central nervous system (CNS) metastases with following exceptions:A. Clinically stable MRI scans (at least 2 consecutive scans within prior 6 months including 1 scan within 28 days prior to screening) and no progressive or uncontrolled neurologic symptoms or signs (e.g., seizures, headaches, central nausea/emesis, progressive neurologic deficits, papilledema) for at least 4 weeks prior to the first study treatment;
• Patients with uncontrolled pleural effusion, pericardial effusion or abdominal effusion (requiring repeated drainage, more than one month or more frequently) as judged by the investigator at screening;
• Patients with untreated or clinically uncontrolled spinal cord compression (except for those who have been treated and have stable symptoms and image for at least 4 weeks before the first dose, and no evidence of cerebral edema, and no need for glucocorticoid therapy);
• Concurrent malignancy within 5 years prior to entry, except for adequately treated cervical carcinoma-in-situ, localized squamous cell cancer of the skin, basal cell carcinoma;
• Moderate to severe dyspnea at rest, severe primary lung disease required for continuous oxygen therapy, or clinically active interstitial lung disease (ILD) or pneumonia due to advanced cancer or its complications; ≥ Grade 3 interstitial pneumonia during previous anti-tumor treatment;
• History of moderate to severe dyspnea at rest due to advanced cancer or their complications, severe primary lung disease, current need of continuous oxygen therapy, or clinically active interstitial lung disease (ILD) or pneumonitis.
• Severe infection within 4 weeks before the first dose, including but not limited to bacteremia requiring hospitalization, severe pneumonia, etc.; active infection with CTCAE ≥ grade 2 requiring systemic antibiotics within 2 weeks before the first dose；
• History of serious cardiovascular and cerebrovascular diseases, including but not limited to: severe heart rhythm or conduction abnormalities, such as ventricular arrhythmia requiring clinical intervention, II-III degree atrioventricular block, etc.; acute coronary syndrome, congestive heart failure, aortic dissection, stroke or other grade 3 and above cardiovascular and cerebrovascular events within 6 months before the first dose; New York Heart Association (NYHA) functional classification ≥ II or left ventricular ejection fraction (LVEF) \< 50% or clinically uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg);
• Patients who have any known liver disease, including chronic hepatitis B (HBsAg positive and HBV DNA ≥ ULN of local site and excluding hepatitis caused by drugs or other reasons), hepatitis C, autoimmune hepatic disorders, primary biliary cirrhosis or sclerosing cholangitis; Patients who have concurrent, serious, uncontrolled infections or known infection with HIV, or have a diagnosed acquired immunodeficiency syndrome (AIDS); or an uncontrolled autoimmune disease, or have undergone organ transplant；
• Syphilis positive patients at screening；
• Patients with active autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.) at screening, or have suffered from autoimmune diseases that may relapse, except for patients with clinically stable autoimmune thyroid disease；
• History of immunodeficiency disease , including positive human immunodeficiency virus (HIV) serum test；
• Patients who have experienced bleeding symptoms of significant clinical significance within 3 months before the first dose; Subjects who had a significant cough of blood and hemoptysis of half a teaspoon (2.5 mL) or more per occasion within 4 weeks prior to the first dose of study drug; arterial/venous thrombotic events such as cerebrovascular accident, deep venous thrombosis, pulmonary embolism within 6 months prior to the first dose; and those who were receiving anticoagulant therapy at screening；
• Patients who have received systemic immunosuppressive therapy (including but not limited to glucocorticoids, cyclophosphamide, azathioprine, methotrexate, thalidomide, etc.) within 2 weeks before the first dose；

Sponsors & Collaborators

• Letolab: lead

Central Study Contacts

Jinying Zhou

CONTACT

+8618911370622; zhoujinying@letolab.net

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Participants will be assigned to sequentially escalating dose cohorts of LTC004

Study Record Dates

• First Submitted: November 10, 2022
• First Posted: December 28, 2022
• Study Start: December 1, 2022
• Primary Completion: December 1, 2024
• Study Completion: December 1, 2024
• Last Updated: December 28, 2022

Record last verified: 2022-12